Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical …

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double-blind placebo-controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD Gel) in children ages three to 17 with full mutation Fragile X syndrome (FXS). FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and is the most common known single-gene cause of autism spectrum disorder. Top-line results are expected in the second half of 2019.

“We are excited to initiate CONNECT-FX, the first-of-its-kind clinical study evaluating transdermally-delivered ZYN002 as a treatment for the debilitating behaviors associated with Fragile X syndrome,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We look forward to demonstrating the clinical effects

... read more at: http://mychesco.com/a/news/business/zynerba-pharmaceuticals-initiates-connect-fx-a-pivotal-clinical-trial-of-zyn002-in-fragile-x-syndrome/